ライフサイエンスコーパス: complement-mediated

1 globulin G2a (IgG2a), and neutralization was complement mediated.

2 Thus, complement-mediated activation of iPLA(2)gamma is mediat

3 specific antibodies inhibited both cell-free complement-mediated and cell-dependent opsonophagocytic

4 ssified to reflect the underlying cause as a complement-mediated and immune complex-mediated disease.

5 ades, which act to protect the parasite from complement-mediated and osmotic lysis.

6 sis is based primarily on in vitro assays of complement-mediated and phagocytic killing.

7 In the CNS, NMO-IgG causes complement-mediated astrocyte damage, inflammatory cell

8 ty against M. catarrhalis through increasing complement-mediated attack, improving phagocytic killing

9 a bacterial immune evasion mechanism against complement-mediated bacterial clearance because FH is a

10 g factor H function, but it can also improve complement-mediated bacterial clearance.

11 446 proteins) provided no protection against complement-mediated bacterial killing.

12 e resulting mouse and rabbit antisera showed complement-mediated bactericidal activity against the ho

13 serum concentrations of fH and its effect on complement-mediated bactericidal activity are unknown.

14 r polysaccharide was also protective against complement-mediated bactericidal activity in human ascit

15 on and has been shown to be resistant to the complement-mediated bactericidal activity of human serum

16 ein (FHbp) expression that were resistant to complement-mediated bactericidal activity of sera from m

17 -fHbp monoclonal antibodies (MAbs) had human complement-mediated bactericidal activity only if the MA

18 Ab502, which did not inhibit fH binding, had complement-mediated bactericidal activity only when test

19 fH, the bacteria became more susceptible to complement-mediated bactericidal activity.

20 ntributes to the resistance of AB307-0294 to complement-mediated bactericidal activity.

21 antibodies (MAbs) tested and elicited serum complement-mediated bactericidal antibody titers in wild

22 f lipid A increases gonococcal resistance to complement-mediated bacteriolysis and cationic antimicro

23 tant was not due to increased sensitivity to complement-mediated bacteriolysis, a result that is cons

24 E. coli-challenged baboons, implying reduced complement-mediated bacteriolysis, whereas treated anima

25 H, which enables the meningococcus to resist complement-mediated bacteriolysis.

26 reases the susceptibility of the organism to complement-mediated bacteriolysis.

27 wild-type erythrocytes to classical pathway complement-mediated C3 deposition in vitro.

28 recently reclassified as alternative pathway complement-mediated C3 glomerulopathy (C3G) and immune c

29 is classified as immune complex-mediated or complement-mediated (C3 glomerulopathy).

30 Our data suggest a major role for complement-mediated cell death in ischemic brain injury

31 he surface of HCV-infected cells may inhibit complement-mediated cell killing.

32 PC lineage cells through A2B5+, O4+, and O1+ complement-mediated cell lysis resulted in a delay in de

33 st abundant human matrix metalloproteases or complement-mediated cell lysis.

34 dent cellular phagocytosis, and Ab-dependent complement-mediated cell lysis.

35 r H (FH) onto the bacterial surface to evade complement-mediated cell lysis.

36 Complement-mediated chemotaxis is essential for many inf

37 rOmpB, and suggest that the ability to evade complement-mediated clearance from the hematogenous circ

38 sident macrophages play an important role in complement-mediated clearance, the receptors coordinatin

39 to prevent Crry-deficient erythrocytes from complement-mediated clearance.

40 ower respiratory tract by protecting against complement-mediated control and clearance.

41 colonic damage via the production of IgM and complement-mediated control of intestinal bacteria.

42 n the other hand, GEF-H1 knockdown augmented complement-mediated cytolysis, suggesting a role for GEF

43 is(y/b) directly, as well as by antibody and complement mediated cytotoxicity (ADCC/CDC), but failed

44 s and in physiologic conditions the superior complement mediated cytotoxicity induced by OFA alone co

45 strated sensitivity of cultured LAM cells to complement mediated cytotoxicity via GD3 antibodies.

46 1 molecules impairs their efficacy to induce complement-mediated cytotoxicity (CDC).

47 body-dependent cellular phagocytosis but not complement-mediated cytotoxicity against CLL cells.

48 We found that several antibodies activate complement-mediated cytotoxicity and that T cells carryi

49 ha-gal Abs target Plasmodium sporozoites for complement-mediated cytotoxicity in the skin, immediatel

50 endent cell-mediated cytotoxicity (ADCC) and complement-mediated cytotoxicity in vitro, and for anti-

51 Consequently, complement-mediated cytotoxicity was attenuated.

52 mediated ADCC, and a 2.5-fold improvement in complement-mediated cytotoxicity while maintaining restr

53 involvement of antibody-dependent cell- and complement-mediated cytotoxicity.

54 ought to elicit transplant rejection through complement mediated damage of the endothelium of the gra

55 rane protein, protects autologous cells from complement-mediated damage by inhibiting complement comp

56 We show that eculizumab protects against complement-mediated damage in murine MFS, providing the

57 treatment, but novel treatments that reduce complement-mediated damage or inhibit the binding of pat

58 o prevent C3b amplification, thus minimising complement-mediated damage to host.

59 Complement-mediated damage to the retinal pigment epithe

60 d by pressure disruption, hypoxic injury, or complement-mediated damage were capable of activating th

61 docytes where acute activation protects from complement-mediated damage, but chronic overactivation l

62 mplement proteins that could protect against complement-mediated damage.

63 cent synapses with enhanced vulnerability to complement-mediated degeneration, is highly dependent on

64 has been hypothesized that B. hermsii evades complement-mediated destruction by binding factor H (FH)

65 complement mediated lysis and inhibited the complement-mediated destruction of common gut bacteria.

66 0 is immunologically active and leads to the complement-mediated destruction of Env-expressing cells.

67 with crossmatch-incompatible sera indicated complement-mediated destruction of Fs-positive erythrocy

68 thogen survival is dependent upon evasion of complement-mediated destruction.

69 e are also new opportunities to intervene in Complement-mediated disease.

70 ave important implications for understanding complement-mediated diseases because, depending on the c

71 hows remarkable clinical benefits in certain complement-mediated diseases.

72 ates for therapeutic development in numerous complement-mediated diseases.

73 for the description and management of other complement-mediated diseases.

74 way toward new options for the treatment of complement-mediated diseases.

75 ge between different types of thrombotic and complement-mediated disorders.

76 0 mg/kg) of the anti-C1s antibody BIVV009 in complement-mediated disorders.

77 (triplex association) and (ii) Watson-Crick complement-mediated displacement of the TFO and replacem

78 C proliferation and angiogenesis rather than complement-mediated EC lesions.

79 gainst FKHR attenuated the effect of VEGF on complement-mediated EC lysis and monocyte adhesion, resp

80 e susceptible than wild-type erythrocytes to complement-mediated elimination as they had a shorter ha

81 ytes were susceptible to alternative pathway complement-mediated elimination in vivo.

82 fection of adult hippocampal neurons induces complement-mediated elimination of presynaptic terminals

83 Properdin deficiency rescued mice from AP complement-mediated embryonic lethality caused by defici

84 exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.

85 tes, which are known to be susceptible to AP complement-mediated extravascular hemolysis.

86 gamma (iPLA2gamma) is cytoprotective against complement-mediated GEC injury.

87 gamma (iPLA2gamma) is cytoprotective against complement-mediated glomerular epithelial cell injury.

88 Here, we report an autosomal dominant complement-mediated GN associated with abnormal increase

89 t only confirm the critical role of C5b-9 in complement-mediated hemolysis and but also highlight the

90 l nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and inhibited both C3 frag

91 8.4.2 was a potent AP inhibitor that blocked complement-mediated hemolysis in several species.

92 d LA-CFH both performed poorly at preventing complement-mediated hemolysis of ES PspCN, a CFH-binding

93 Complement mediated hemolytic uremic syndrome (aHUS) acc

94 In vitro complement-mediated hemolytic assays with mouse compleme

95 l determinant for pneumococcal resistance to complement-mediated host defense in humans.

96 Complement mediated HUS (aHUS) has a worse prognosis com

97 This may have implications for modulating complement-mediated immune function in the microenvironm

98 ent, provides a powerful approach to inhibit complement-mediated immune responses and tissue injury.

99 A, the main pneumococcal autolysin, inhibits complement-mediated immunity independently of effects on

100 rovide insight into bacterial suppression of complement-mediated immunity, we present here structures

101 ectively protects virus particles from serum complement-mediated inactivation.

102 ight into the molecular processes underlying complement-mediated inflammation and highlight the possi

103 Complement-mediated inflammation exacerbates the tissue

104 and tangles in AD brain, and thus a role for complement-mediated inflammation in the acceleration or

105 HR1, which could result in an enhanced local complement-mediated inflammation, endothelial cell activ

106 plored as noninvasive in vivo diagnostics of complement-mediated inflammation, for spatiotemporal mon

107 n example of repetitive formation of ICs and complement-mediated inflammation.

108 ed to cells and is an excellent biomarker of complement-mediated inflammation.

109 t contribute to the pathogenic mechanisms in complement-mediated, inflammatory diseases.

110 Complement mediated injury of the neuromuscular junction

111 ctivation leads to endothelial resistance to complement-mediated injury and protects from atherogenes

112 ystemic properdin as a key contributor to AP complement-mediated injury and support its therapeutic t

113 ctor (DAF or CD55) protects host tissue from complement-mediated injury by inhibiting the classical a

114 er endothelial cells and are associated with complement-mediated injury of the kidneys and vasculatur

115 HO-1)), which are particularly vulnerable to complement-mediated injury owing to their terminally dif

116 a compelling hypothesis for how FH prevents complement-mediated injury to host tissue while lacking

117 To establish the contribution of complement-mediated injury to the allograft microcircula

118 expression of TRPC6 protected podocytes from complement-mediated injury, whereas genetic or pharmacol

119 d this structure thus remained vulnerable to complement-mediated injury.

120 otor nerve terminal membrane might attenuate complement-mediated injury.

121 surface DAF and enhanced protection against complement-mediated injury.

122 d for IL-4-induced resistance of ECs against complement-mediated injury.

123 ve shown that S. pneumoniae is able to evade complement-mediated innate immunity by recruiting comple

124 fected mice present a specific inhibition of complement-mediated internalization of IC caused by the

125 nal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis because of t

126 nal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis due to the l

127 59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process c

128 al manifestations of the disease result from complement-mediated intravascular hemolysis.

129 introduction of a therapeutic that prevents complement-mediated intravascular hemolysis.

130 ation between these genetic observations and complement-mediated kidney disease, these results provid

131 expression, binding of alemtuzumab and both complement-mediated killing and Ab-dependent cell-mediat

132 Both complement-mediated killing and cell-surface binding wer

133 otect pathogens from host defenses including complement-mediated killing and phagocytosis and therefo

134 and increased sensitivity of both strains to complement-mediated killing and the aminoglycoside antib

135 c acid had negative effects on resistance to complement-mediated killing and viability of biofilms in

136 rotein was essential for Y. pestis to resist complement-mediated killing at 26 and 37 degrees C.

137 hat exhibited an increased susceptibility to complement-mediated killing by neutrophils.

138 polyamines increase gonococcal resistance to complement-mediated killing by normal human serum.

139 possessed gonococcal Por1B were resistant to complement-mediated killing by normal human serum.

140 also resulted in decreased susceptibility to complement-mediated killing by normal human serum.

141 The P6 mutant was more sensitive to complement-mediated killing by normal human serum.

142 and several pathogens have adapted to avoid complement-mediated killing by sequestering fH to their

143 s increased resistance to antibody-dependent complement-mediated killing compared with enterocolitis-

144 The susceptibility to complement-mediated killing correlated with the amount o

145 the resistance of pathogenic leptospires to complement-mediated killing during leptospiremic phases

146 equired for resistance to antibody-dependent complement-mediated killing in a murine model of infecti

147 cate this protection involves a mechanism of complement-mediated killing in mammalian blood, a means

148 s to the ability of N. meningitidis to avoid complement-mediated killing in the presence of human ser

149 t component C3 deposition on the surface and complement-mediated killing of B. parapertussis.

150 terium from other antibodies that can induce complement-mediated killing of bacteria.

151 Antibodies that initiate complement-mediated killing of Neisseria meningitidis as

152 tibodies exhibited potent antibody-dependent complement-mediated killing of nonmucoid bacteria, they

153 Complement-mediated killing of Salmonella by healthy ser

154 fever, Rickettsia conorii, is susceptible to complement-mediated killing only in the presence of spec

155 Strains that resist antibody-induced, complement-mediated killing produce lipopolysaccharide c

156 t increased resistance to antibody-dependent complement-mediated killing secondary to genetic deletio

157 d-type strains were more resistant to direct complement-mediated killing than their siaB mutants.

158 D59 expression, sensitizing neuroblastoma to complement-mediated killing triggered by anti-GD2 therap

159 e mechanisms by which N. meningitidis avoids complement-mediated killing, and how polymorphisms in ge

160 meningitidis has several strategies to evade complement-mediated killing, and these contribute to its

161 ection E. coli strain to become sensitive to complement-mediated killing.

162 tigen chain length and confers resistance to complement-mediated killing.

163 ibutes to the ability of gonococci to resist complement-mediated killing.

164 recipients given alemtuzumab without risk of complement-mediated killing.

165 everity, and did not mediate protection from complement-mediated killing.

166 nd membrane attack complex deposition and to complement-mediated killing.

167 ction E. coli strains were more sensitive to complement-mediated killing.

168 Nm Opc binds to serum vitronectin to inhibit complement-mediated killing.

169 acid has been shown to protect bacteria from complement-mediated killing.

170 nesis of UTI and provides protection against complement-mediated killing.

171 nd the rck gene, features that resist direct complement-mediated killing.

172 l tract, perhaps via increased resistance to complement-mediated killing.

173 ance to temperature stress and resistance to complement-mediated killing.

174 sistant to its host's alternative pathway of complement-mediated killing.

175 oyed by the Lyme disease spirochete to evade complement-mediated killing.

176 f the cytokine and prolonged protection from complement-mediated killing.

177 hypothesized to protect the spirochete from complement-mediated killing.

178 saccharide (LOS), facilitating resistance to complement-mediated killing.

179 spiratory tract, and confers protection from complement-mediated killing.

180 ncluding protection of E. coli DH5alpha from complement-mediated killing.

181 o identify genes important for resistance to complement-mediated killing.

182 ion, antibody can protect the bacterium from complement-mediated killing.

183 n (methicillin) as well as susceptibility to complement-mediated killing.

184 s is resistant to the alternative pathway of complement mediated-killing, while nonpathogenic members

185 ammatory response of microglia is leading to complement-mediated loss of dopaminergic neurons.

186 mouse complement in vivo and to protect from complement-mediated lung injury but the mechanism of suc

187 re, was impaired in their ability to mediate complement mediated lysis and inhibited the complement-m

188 sis were reduced in their ability to mediate complement mediated lysis of target cells.

189 and, as a result, escape antibody-dependent complement-mediated lysis (ADCML).

190 ctivation (RCA) to resist antibody-dependent complement-mediated lysis (ADCML).

191 Binding of C1q to target-bound IgG initiates complement-mediated lysis (CML) of pathogens, as well as

192 infected patients became highly sensitive to complement-mediated lysis activated by either anti-HIV-1

193 c or bind host molecules function to prevent complement-mediated lysis and phagocytosis.

194 asured by enzyme-linked immunosorbent assay, complement-mediated lysis assay, and antibody-dependent

195 diverse microorganisms for phagocytosis and complement-mediated lysis by binding specific surface gl

196 I and III cells become highly susceptible to complement-mediated lysis by nonacidified normal human s

197 enes demonstrated significant sensitivity to complement-mediated lysis compared with wild-type Schu S

198 We also found that mAb 2E8 caused complement-mediated lysis in DENV-infected cells.

199 Loss of CD55 and CD59 on erythrocytes causes complement-mediated lysis in paroxysmal nocturnal hemogl

200 la activate complement, but are resistant to complement-mediated lysis in part due to limited C3 depo

201 The strains with IS1301 in the IGR avoided complement-mediated lysis in the presence of bactericida

202 RA, and that these cells are susceptible to complement-mediated lysis in the presence of infliximab

203 a-CRIg inhibited MAC formation and prevented complement-mediated lysis in vitro.

204 educed immune complex precipitation, blocked complement-mediated lysis of Ab-sensitized RBC, and inhi

205 The CD20 mAb ofatumumab (OFA) induces complement-mediated lysis of B cells.

206 nti-HIV-1 Abs and complement did not mediate complement-mediated lysis of either erythrocytes or peri

207 ial virulence and is known to interfere with complement-mediated lysis of erythrocytes, but its exact

208 d ability of C1-INH to inhibit the classical complement-mediated lysis of erythrocytes.

209 ally significant, reducing C9 deposition and complement-mediated lysis of flow-conditioned endothelia

210 Furthermore, mini-FH efficiently inhibited complement-mediated lysis of host-like cells caused by a

211 Their ability to mediate complement-mediated lysis of human monocytes and lymphoc

212 20 to normal human serum leads to aggressive complement-mediated lysis of normally nonactivating shee

213 eated promastigotes were more susceptible to complement-mediated lysis than untreated controls and re

214 ated protection of endothelial cells against complement-mediated lysis was not.

215 including but not limited to (i) evasion of complement-mediated lysis, (ii) facilitation of macropha

216 protein that protects epithelial cells from complement-mediated lysis, also functions as a receptor

217 hancing protection against C3 deposition and complement-mediated lysis, and this was reversed by DAF

218 ctica live vaccine strain) were resistant to complement-mediated lysis, but LVSG and LVSR (LVS strain

219 e examine the mechanisms of Ft resistance to complement-mediated lysis, C3 component deposition on th

220 e against invading microorganisms, including complement-mediated lysis, engulfment, formation of neut

221 rane protein that protects Y. pestis against complement-mediated lysis, on bubonic plague pathogenesi

222 h Ft.LVS, the mutant was highly sensitive to complement-mediated lysis, significantly attenuated in v

223 pendent cellular cytotoxicity, and by direct complement-mediated lysis.

224 antibody-dependent cellular cytotoxicity and complement-mediated lysis.

225 VCP was found to protect infected cells from complement-mediated lysis.

226 ors, regulation of apoptosis, and evasion of complement-mediated lysis.

227 ommodation" conferring protection against Ab/complement-mediated lysis.

228 ith recombinant Bsp protected 4T1 cells from complement-mediated lysis.

229 rds P. falciparum merozoites protection from complement-mediated lysis.

230 or I contributes to S. aureus virulence by a complement-mediated mechanism.

231 In this study, we have defined complement-mediated mechanisms that enhance PGA formatio

232 important convergence point for antibody and complement mediated membrane injury in general, it forms

233 DM is an undeniably a complement-mediated microangiopathy with destruction of

234 There were 23 patients with complement-mediated MPGN and available eye examination r

235 classification system, and all patients with complement-mediated MPGN require screening eye examinati

236 ities are more prominent among patients with complement-mediated MPGN when compared with patients wit

237 These results demonstrate that complement-mediated muscle injury is central to the path

238 ling in mice exposed to AGAbs indicates that complement-mediated necrosis occurs extensively in the p

239 They also define pathways of virus complement-mediated neutralization and suggest the desig

240 Viruses have evolved mechanisms to limit complement-mediated neutralization, some of which involv

241 ibution of these regulators in resistance to complement-mediated neutralization.

242 atant to protect the IMV, upon release, from complement-mediated neutralization.

243 into progeny virions as a mechanism to limit complement-mediated neutralization.

244 e gC and gE are postulated to interfere with complement-mediated neutralization.

245 lement component C3b and protects virus from complement-mediated neutralization.

246 we tested the in vitro sensitivity of NiV to complement-mediated neutralization.

247 The reduced capacity of complement-mediated opsonization and phagocytosis in the

248 Bacteria can avoid complement-mediated opsonization and phagocytosis throug

249 a FH, which may contribute to GAS evasion of complement-mediated opsonization and phagocytosis.

250 Complement-mediated opsonization, phagocytosis, and immu

251 ly encapsulated based on their resistance to complement-mediated opsonophagocytic killing and their f

252 by approximately 50%, but did not influence complement-mediated opsonophagocytic killing by human ne

253 apsulated ATCC 15305 strain was resistant to complement-mediated opsonophagocytic killing by human ne

254 iofilm formation but was more susceptible to complement-mediated opsonophagocytic killing than the pa

255 Evasion of complement-mediated opsonophagocytosis enables group A S

256 nt bound more C3 and was more susceptible to complement-mediated opsonophagocytosis than the parent s

257 either serotype C or D are more resistant to complement-mediated opsonophagocytosis than unencapsulat

258 a variety of functions including evasion of complement-mediated parasite-killing and host intramacro

259 w that zymosan-, immunoglobulin G (IgG)- and complement-mediated particle binding and phagocytosis we

260 However, its role in inflammation beyond complement-mediated pathogen clearance remains poorly de

261 Understanding the complexity of complement-mediated pathological mechanisms will aid in

262 ted the most attention, the diverse array of complement-mediated pathologies, with distinct underlyin

263 In GECs that overexpress iPLA(2)gamma, complement-mediated PGE(2) production was reduced by inh

264 ) integrin-mediated signaling cascade during complement-mediated phagocytosis and firm adhesion of po

265 c is able to rescue actin polymerization and complement-mediated phagocytosis in Vav-deficient macrop

266 ffect alveolar macrophage viability, reduced complement-mediated phagocytosis of S. pneumoniae, while

267 ng ClfA(P336A Y338S) was more susceptible to complement-mediated phagocytosis than a ClfA-null mutant

268 Nonetheless, complement-mediated phagocytosis was enhanced within eac

269 bionts exhibited increased resistant against complement-mediated phagocytosis, and their intravenous

270 the capacity of capsular PS to interfere in complement-mediated phagocytosis, inhibit nitric oxide p

271 n contrast, Vav is specifically required for complement-mediated phagocytosis, suggesting that Rac is

272 usly opsonized with antibody but never after complement-mediated phagocytosis.

273 ino mouse model may be a good model to study complement-mediated photoreceptor degeneration.

274 strategy aimed to protect donor kidney from complement-mediated postischemic damage and therefore in

275 fficient mice, indicating a limited role for complement-mediated processes.

276 Complement-mediated production of PGE(2) was amplified i

277 These data demonstrate a critical role for complement-mediated regulation of the IL-23-T(H)17 axis

278 alternative pathway is the main trigger for complement-mediated rejection.

279 This is particularly so in the case of complement-mediated renal disease, where distinct sites

280 The complement-mediated renal diseases C3 glomerulopathy (C3

281 uraemic syndrome (aHUS) as well as the other complement-mediated renal diseases, including dense depo

282 Our results suggest that complement-mediated retention of viral antigens by strom

283 RPC-reactive IgG levels induced more severe complement-mediated RPC damage than those with lower RPC

284 s demonstrated that the classical pathway of complement mediated serum neutralization of influenza vi

285 the fH binding site, which result in greater complement-mediated serum bactericidal activity; these e

286 M. catarrhalis usually resists complement-mediated serum killing by recruiting to its s

287 bute to the ability of the organism to evade complement-mediated serum killing.

288 role of cytochrome P450 2B1 (CYP2B1) in this complement-mediated sublytic injury.

289 complement for elimination and suggest that complement-mediated synapse elimination may become aberr

290 ation of similar developmental mechanisms of complement-mediated synapse elimination potentially driv

291 Anti-CD45 antibody plus complement-mediated targeting of donor tissue is the mos

292 Eculizumab inhibited complement-mediated thrombotic microangiopathy and was a

293 enetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy.

294 ical work-up of patients suspected of having complement-mediated TMA.

295 duration of cold ischemia and the extent of complement-mediated tubule damage and loss of graft func

296 Although complement-mediated uptake requires macrophages to be PM

297 c enveloped viruses, including HIV-1, escape complement-mediated virolysis by incorporating host cell

298 of the viral envelope confers resistance to complement-mediated virolysis, which may explain why hum

299 oximately 10-fold range in their potency for complement-mediated virus neutralization.

300 ation of complement pathways, and subsequent complement-mediated virus neutralization.